This is a working overview of DAC, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH analog, not a steroid |
| Backbone length | 29 amino acids | Based on GRF(1-29) |
| Substitutions | Four positions | D-Ala2, Gln8, Ala15, Leu27 |
| Appearance | White to off-white powder | Typical lyophilized research material |
| Common synonyms | Modified GRF(1-29) | Usage varies between sources |
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
== Evolution and species distribution == Insulin may have originated more than a billion years ago. The molecular origins of insulin go at least as far back as the simplest unicellular eukaryotes. Apart from animals, insulin-like proteins are also known to exist in fungi and protists. Insulin is produced by beta cells of the pancreatic islets in most vertebrates and by the Brockmann body in some teleost fish. Cone snails: Conus geographus and Conus tulipa, venomous sea snails that hunt small fish, use modified forms of insulin in their venom cocktails. The insulin toxin, closer in structure to fishes' than to snails' native insulin, slows down the prey fishes by lowering their blood glucose levels.
It typically appears in the form of a white or brown powder. Treatment of heroin addiction often includes behavioral therapy and medications. Medications can include buprenorphine, methadone, or naltrexone. A heroin overdose may be treated with naloxone. As of 2015, an estimated 17 million people use opiates non-medically, of which heroin is the most common, and opioid use resulted in an estimated 109 thousand to 129 thousand deaths in 2015. The total number of heroin users worldwide is believed to have increased in Africa, the Americas, and Asia between 2000 and 2015. In the United States, approximately 1.6 percent of people reported using heroin at some point in their lives and 0.4% of people aged 12 or older in 2021 reported using heroin in the past 12 months. When people die from overdosing on a drug, the drug is usually an opioid and often heroin. Heroin was first made by C. R. Alder Wright in 1874 from morphine, a natural product of the opium poppy. Internationally, heroin is controlled under Schedules I and IV of the Single Convention on Narcotic Drugs, and it is generally illegal to make, possess, or sell without a license. About 448 tons of heroin were made in 2016. In 2015, Afghanistan produced about 66% of the world's opium. Illegal heroin is often mixed with other substances such as sugar, starch, caffeine, quinine, or other opioids like fentanyl.
== Growth and morphology == Rhizopus oryzae grows quickly in optimal temperatures, at 1.6 mm per hour (nearly 0.5 μm per second - enough to be able to directly visualize hyphal elongation in real-time under the microscope). R. oryzae can grow in temperature of 7 °C to 44 °C and the optimum growth temperature is 37 °C. There is very poor growth from 10 °C to 15 °C and negligible growth at 45 °C. There is substantial growth in media containing 1% NaCl, very poor growth at 3% NaCl, and none at 5% NaCl. R. oryzae favors slightly acidic media. Good growth is observed at a pH of 6.8; in the range of 7.7-8.1, there is very poor growth. Most amino acids—with the exception of L-valine—promote R. oryzae growth, with L-tryptophan and L-tyrosine being the most effective. It also grows well on mineral nitrogen sources, except nitrate, and can utilize urea. Rhizopus oryzae has variable sporangiosphores. They can be straight or curved, swollen or branched, and the walls can be smooth or slightly rough. The colour of sporangiosphores range from pale brown to brown. Sporangiosphores grow between 210-2500 μm in length and 5-18 μm in diameter. The sporangia in R. oryzae are globose or subglobose, wall spinous and black when mature, 60-180 μm in diameter. They can be distinguishable from Rhizopus stolonifer as they have smaller sporangia and spores. The optimal conditions for sporangium production are temperatures between 30 °C to 35 °C and low water levels.
It results from the slowing of peristalsis in the gut and is a reason dihydrocodeine, ethylmorphine, codeine, opium preparations, and morphine are used to stop diarrhoea and combat irritable bowel syndrome (IBS) in its diarrhoeal and cyclical forms as well as other conditions causing hypermotility or intestinal cramping. Opium/opioid preparations are used often as a last resort where pain is severe and the bowels are organically loose. It is generally better to treat IBS with a non psycho-tropic opioid such as loperamide hydrochloride which stays contained in the bowel, thereby not causing drowsy effects and allowing many people to work using machines etc. For IBS, hyoscine butylbromide (Buscopan in the UK) and mebeverine hydrochloride (Colofac) can be effective with or without an opium related compound.
Making strong appeals to Black voters on the campaign trail and in the South Carolina debate, Biden won the South Carolina primary by more than 28 points. After the withdrawals and subsequent endorsements of candidates Pete Buttigieg and Amy Klobuchar, he made large gains in the Super Tuesday primaries. Biden won 18 of the next 26 contests, putting him in the lead. Elizabeth Warren and Michael Bloomberg soon dropped out, and Biden expanded his lead with victories over Sanders in four states on March 10. In March 2020, Biden said, "I view myself as a bridge, not as anything else. There's an entire generation of leaders you saw stand behind me. They are the future of this country." In late March 2020, Tara Reade, one of the eight women who in 2019 had accused Biden of inappropriate physical contact, accused Biden of having sexually assaulted her in 1993. There were inconsistencies between Reade's 2019 and 2020 allegations. Biden and his campaign denied the sexual assault allegation. When Sanders suspended his campaign on April 8, 2020, Biden became the Democratic Party's presumptive nominee. On April 13, Sanders endorsed Biden. Barack Obama endorsed Biden the next day. There was a great deal of interest in who his running mate would be, in part because of "the expectation, downplayed but not exactly denied by the Biden campaign, that the 77-year-old would be a one-term president".
Sources: en.wikipedia.org
Hindu-Arabic numerals were not originally designed to indicate their numeric value through the number of angles they contain. There are no historical records of this, and the myth is difficult to reconcile with digits past 3 or 4. The Greek philosopher Pythagoras was not the first to discover what is now called the Pythagorean theorem, as it was known and used by the Babylonians and Indians centuries before him. Pythagoras may have been the first to introduce it to the Greeks, but the first record of it being mathematically proven as a theorem is in Euclid's Elements which was published some 200 years after Pythagoras. There is no evidence that the ancient Greeks deliberately designed the Parthenon to match the golden ratio. The Parthenon was completed in 438 BCE, more than a century before the first recorded mention of the ratio by Euclid. Similarly, Leonardo da Vinci's Vitruvian Man makes no mention of the golden ratio in its text, although it describes many other proportions. The repeating decimal written as 0.999... represents exactly the same quantity as 1. The p-value is not the probability that the null hypothesis is true, or the probability that the alternative hypothesis is false; it is the probability of obtaining results at least as extreme as the results actually observed under the assumption that the null hypothesis was correct, which can indicate the incompatibility of results with the specific statistical model assumed in the null hypothesis. This misconception, and similar ones like it, contributes to the common misuse of p-values in education and research.
Desloratadine exhibits only peripheral activity since it does not readily cross the blood–brain barrier; hence, it does not normally cause drowsiness because it does not readily enter the central nervous system. Desloratadine does not have a strong effect on a number of tested enzymes in the cytochrome P450 system. It was found to weakly inhibit CYP2B6, CYP2D6, and CYP3A4/CYP3A5, and not to inhibit CYP1A2, CYP2C8, CYP2C9, or CYP2C19. Desloratadine was found to be a potent and relatively selective inhibitor of UGT2B10, a weak to moderate inhibitor of UGT2B17, UGT1A10, and UGT2B4, and not to inhibit UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT2B7, UGT2B15, UGT1A7, and UGT1A8.
== History == The American professional wrestling promotion WWE (formerly World Wrestling Federation, or WWF) has been broadcasting pay-per-view (PPV) events since the mid 1980s, when its classic "Big Four" events (Royal Rumble, WrestleMania, SummerSlam, and Survivor Series) were first established between 1985 and 1989—with the company's very first PPV being WrestleMania in 1985. The company's PPV lineup expanded to a monthly basis in 1995 following the introduction of the In Your House series of pay-per views (which were replaced by standalone ppvs in 1999) before expanding even further in the mid-2000s during the first WWE brand extension. In addition, WWE produced international PPVs not available in the United States between 1997 and 2003. In 2022, the company began recognizing Money in the Bank as one of their five biggest events of the year, thus making it a "Big Five" event along with the classic "Big Four"; King of the Ring was considered a "Big Five" event from 1993 until 2002, after which, it was discontinued as a PPV until 2024. Following WWE's original brand extension in 2002, the company promoted two touring rosters, Raw and SmackDown, representing its television programs, Raw and SmackDown, with the two United Kingdom PPVs held that year being the first ones to be brand exclusive. Following Judgment Day in 2003, brand-exclusive PPVs were expanded to all WWE PPVs, except the traditional "Big Four", which continued to showcase the entire roster, while the remaining PPVs alternated between Raw and SmackDown.
== Early life == Shapiro was born in Springfield, Massachusetts in 1965, and later moved to Seattle, where he worked for many years in the 1980s and '90s. In 1987, Shapiro helped launch the Annex Theatre in Seattle and performed in many of their productions. In the 1990s, he also did some acting work for Microsoft, including as the voice of McZee in 3D Movie Maker in 1995, and as the host of the MSN Preview in 1996. Shapiro moved to Brooklyn, New York in 2000.
=== Production of ethanolamines === In the industry, ethanolamines (mono-, di-, and triethanolamines) are produced by reacting ammonia and ethylene oxide in anhydrous medium at a temperature of 40–70 °C (100–160 °F) and pressure of 1.5–3.5 MPa (220–510 psi) MPa:
Sources: en.wikipedia.org
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.
The original material included a linker that binds serum albumin. A later variant removed that linker to reduce the duration of action. Catalogs and papers did not consistently adopt separate names, so both remain widely labeled with the same term.
The amino acid sequence and the presence or absence of the linker group. Mass measured by spectrometry gives an independent check that separates the two forms.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.